Results from two Pradaxa trials to be presented at WSC
Results from Pradaxa ® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke CongressData from key trials will aid in increasing scientific understanding of ESUS and CVTRESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa ® vs ASA (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 12, 2018 Category: Research Source Type: news

health project elephants
Boehringer Ingelheim increases awareness of health with the micro enterprise project ‘Elephants’ in South IndiaBoehringer Ingelheim launches new health project in Coimbatore/IndiaProject to raise awareness about infections with communicable diseases due to bad hygiene and the importance of handwashing with soap  Trainings will enable participants to start own soap manufacturing business (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 12, 2018 Category: Research Source Type: news

Inauguration of new global center for veterinary vaccine R & D
Boehringer Ingelheim inaugurates its new global centre for veterinary vaccine R&D in Lyon, France70 million euro investment reinforces the company ’s leading position in the veterinary vaccine marketThe new R&D center of 14,500 square meters is a high-tech facility employing more than 200 employees (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 10, 2018 Category: Research Source Type: news

2018 Animal Welfare Medals
: Boehringer Ingelheim recognizes outstanding research in animal healthBoehringer Ingelheim honors research papers on innovative health solutions for improving animal welfareIndependent jury awards prizes in the folowing categories: cattle, equine, swine, as well as small animals and petsThe  awards demonstrate focus on prevention, animal well-being and innovative solutions (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 10, 2018 Category: Research Source Type: news

Empa T1D Full Data
Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to insulin in type 1 diabetesAll investigated doses met the primary efficacy endpoint defined as a change from baseline in HbA1c versus placebo after 26 weeks of treatment  Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes  Full results presented at the 54th European Association for the Study of Diabetes Annual Congress (EASD) and published online in Diabetes Care ahead of print1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 4, 2018 Category: Research Source Type: news

Boehringer Ingelheim is committed to joining forces in the global fight against rabies
The company ’s goal is to bring attention to the serious threat that rabies still poses to animals and humans in many parts of the worldAn estimated 160 people die from rabies every day, 40 per cent of whom are children1Human rabies deaths could be avoided through effective dog vaccination1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 28, 2018 Category: Research Source Type: news

New vaccine against Bovine Respiratory Disease
: Boehringer Ingelheim reaffirms its focus on preventionBovalto ® Respi Intranasal now registered in most European countries for active immunization of cattle against Bovine Respiratory Syncytial Virus (BRSV) and Bovine Parainfluenza 3 Virus (PI3V), two of the major pathogens involved in Bovine Respiratory Disease (BRD)BRD is one of the most common diseases1 affecting cattle all over the worldBoehringer Ingelheim reaffirms its focus on prevention and animal well-being (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 27, 2018 Category: Research Source Type: news

NSCLC_treatment_sequencing_survey
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC  More than one-third of physicians report not having sufficient information to decide on how to sequence specific targeted lung cancer treatmentsSurvey findings presented today as a late-breaking abstract at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 26, 2018 Category: Research Source Type: news

Lume Meso Phase III Results
Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19th World Conference on Lung Cancer (WCLC 2018)The primary endpoint of progression-free survival was not met in the Phase III LUME-Meso Trial (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news

Empa long-term survival benefit
New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular diseaseSurvival estimates from the EMPA-REG OUTCOME ® trial data demonstrate potential long-term benefit of empagliflozin (marketed as Jardiance®) on life expectancy of adults with type 2 diabetes and cardiovascular disease1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news

Carmelina
Boehringer Ingelheim and Lilly present full results of Trajenta ®’s CARMELINA® cardiovascular outcome trial Trajenta ® demonstrated a similar long-term cardiovascular and kidney safety profile compared to placebo in adults with type 2 diabetes1 The results of CARMELINA ® were presented at the 54th EASD Annual Meeting today (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news

Real-world study reports effects of Spiolto Respimat
Large European real-world study reports effects of Spiolto ® Respimat® for people living with COPD in daily clinical practice1OTIVACTO study reported improvements in both physical functioning and general condition in people living with COPD receiving Spiolto ®(tiotropium/olodaterol) Respimat® therapy14 out of 5 patients reported high satisfaction with their Respimat ® inhaler and tiotropium/olodaterol treatment overall1Data presented at European Respiratory Society International Congress 20181 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2018 Category: Research Source Type: news

INSTAGE data for nintedanib in advanced IPF published
Clinical trial data for nintedanib in patients with advanced IPF published   INSTAGE ® trial results published in the New England Journal of Medicine1Trial provides clinical data on patients with IPF and severe impairment in gas exchange usually excluded from clinical trials1Efficacy and safety profile of nintedanib in patients with advanced IPF was consistent with that observed in patients with less advanced disease in earlier trials1,2,3,4Sildenafil plus nintedanib did not provide significant benefit   versus nintedanib alone1  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2018 Category: Research Source Type: news

INPULSIS-ON shows ofev slows progression of IPF
New study results provide evidence that Ofev ® (nintedanib) slows progression of IPF beyond four years with consistent safetyINPULSIS ®-ON study indicates safety and efficacy of Ofev®(nintedanib) are maintained over the long term and consistent with prior findings from INPULSIS® trials1Results from INPULSIS ®-ON, the open-label extension from the two INPULSIS® Phase III trials, published in Lancet Respiratory Medicine1  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 15, 2018 Category: Research Source Type: news

Boehringer Ingelheim acquires all ViraTherapeutics shares
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies  Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeuticsViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim ’s Discovery Research organization, maintaining its innovative biotech heritage and close connections to the Medical University of Innsbruck and the regional scientific communityAcquisition strengthens Boehringer Ingelheim ’s commitment to research and development of viral-based immuno-...
Source: Boehringer Ingelheim Corporate News - September 12, 2018 Category: Research Source Type: news

Cyltezo-Phase III -in Psoriasis
Biosimilar Cyltezo ® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasisData show that Cyltezo © (adalimumab- adbm) and Humira®* have similar efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis1At week 16, the study met the primary endpoint, demonstrating clinical equivalence to Humira ®1Data will be presented at the European Association of Dermatology and Venereology Annual Meeting (EADV 2018) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 12, 2018 Category: Research Source Type: news

Changes to the Leadership of Boehringer Ingelheim
’s Corporate Department Medicine (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 10, 2018 Category: Research Source Type: news

The first liquid solution for hypertension in cats
Boehringer Ingelheim launches the first liquid solution for hypertension in catsSemintra ® 10 mg/ml Oral Solution now licenced to treat and control feline hypertensionA new and easy-to-give solution for a common problem in catsBoehringer Ingelheim continues to set new standards of care to strengthen its commitment to animal welfare (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 4, 2018 Category: Research Source Type: news

New Partnership to Develop Novel Treatment Approaches Against Infectious Diseases
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious DiseasesThe new collaboration aims to develop novel breakthrough therapy approaches applying principles of immune modulation to infectious diseases  Immuno-infection is a new focus area of Boehringer Ingelheim ’s Research Beyond Borders (RBB) department, which explores emerging science and technology beyond the company’s core areas of focusBoehringer Ingelheim and Tsinghua University will establish a Joint Research Center for Immuno-Infection for new therapy concept exp...
Source: Boehringer Ingelheim Corporate News - September 3, 2018 Category: Research Source Type: news

Biologicals_BeiGene_NDA_China
Boehringer Ingelheim Biopharmaceuticals China supports BeiGene in its China NDA submission of anti-PD-1 antibody, tislelizumabFirst biologic manufactured by Boehringer Ingelheim BioChina accepted for New Drug Application reviewImportant milestone for Boehringer Ingelheims ’ collaboration partner BeiGene in immuno-oncologyBoehringer Ingelheim BioChina is proud to support BeiGene in serving patients worldwide with this important medicine   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 3, 2018 Category: Research Source Type: news

new_solids_tablet_ launch_facility_ingelheim
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 21, 2018 Category: Research Source Type: news

Canbridge_contract_bio_manufacturing
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 20, 2018 Category: Research Source Type: news

New data at ESC supports Pradaxa safety profile
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 16, 2018 Category: Research Source Type: news

GioTag
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 8, 2018 Category: Research Source Type: news

New Partnership to Develop Gene Therapy for Cystic Fibrosis
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 6, 2018 Category: Research Source Type: news

Boehringer Ingelheim launches the initiative InReachAfrica
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 30, 2018 Category: Research Source Type: news

H1
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 30, 2018 Category: Research Source Type: news

CARMELINA high level
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 16, 2018 Category: Research Source Type: news

New production center for Veterinary Public Health
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 10, 2018 Category: Research Source Type: news

Biologicals_fill_finish_Shanghai
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 3, 2018 Category: Research Source Type: news

CHMP Positive Opinion
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 28, 2018 Category: Research Source Type: news

World_Scleroderma_Day_2018
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 28, 2018 Category: Research Source Type: news

Atrial Fibrillation Poll
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 26, 2018 Category: Research Source Type: news

Type 1 Diabetes
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 25, 2018 Category: Research Source Type: news

New Biologicals Development Center in Germany announced
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 21, 2018 Category: Research Source Type: news

European Metacam ® indication expanded to guinea pigs
European Metacam ® indication expanded to guinea pigs (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 18, 2018 Category: Research Source Type: news

realgido study results
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 30, 2018 Category: Research Source Type: news

Spiolto Respimat enables greater physical activity
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 22, 2018 Category: Research Source Type: news

efficacy_and_safety_of_OFEV ®_ATS_2018
efficacy_and_safety_of_OFEV ®_ATS_2018 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 17, 2018 Category: Research Source Type: news

Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 16, 2018 Category: Research Source Type: news

Inauguration of new integrated Asian Veterinary R & D Center in China
Inauguration of new integrated Asian Veterinary R&D Center in China (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 15, 2018 Category: Research Source Type: news

annualpressconference
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 25, 2018 Category: Research Source Type: news

Transcending disease boundaries
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 25, 2018 Category: Research Source Type: news

Empa-kidney
EMPA-KIDNEY (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2018 Category: Research Source Type: news

Investment of 65 million euro in avian vaccines in France
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2018 Category: Research Source Type: news

New Partnership to develop novel checkpoint inhibitor
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 4, 2018 Category: Research Source Type: news

Results from landmark DYNAGITO trial
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 28, 2018 Category: Research Source Type: news

Boehringer Ingelheim announces 2018 BVDzero Case Awards
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 28, 2018 Category: Research Source Type: news

Joint Venture Targeting Foot-and-Mouth Disease in China
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 26, 2018 Category: Research Source Type: news

EHRA Congress 2018
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 20, 2018 Category: Research Source Type: news